Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

Abstract

Age-specific and age-adjusted rates were compared by sex and race (white, black, Asian). Age-adjusted trends in incidence were estimated by sex and race using weighted least squares log-linear regression. Diverse incidence patterns and trends were observed by lymphoid neoplasm subtype and population. In the elderly (75 years or older), rates of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma increased 1.4% and 1.8% per year, respectively, whereas rates of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) declined 2.1% per year. Although whites bear the highest incidence burden for most lymphoid neoplasm subtypes, most notably for hairy cell leukemia and follicular lymphoma, black predominance was observed for plasma cell and T-cell neoplasms. Asians have considerably lower rates than whites and blacks for CLL/SLL and Hodgkin lymphoma. We conclude that the striking differences in incidence patterns by histologic subtype strongly suggest that there is etiologic heterogeneity among lymphoid neoplasms and support the pursuit of epidemiologic analysis by subtype. (Blood. 2006;107:265-276)

Distribution of lymphoid neoplasms in the Republic of Korea: Analysis of 5318 cases according to the World Health Organization classification

“…Our findings are in agreement with previous results, showing the relatively higher proportions of patients with overall NHL and T/NK-cell neoplasms, and the relatively lower proportions of patients with FL, CLL/SLL, and HL among Korean individuals compared with those of Western populations (Supplementary Table III) [4][5][6][7][8][9][10][11][12][13][14][15][16][17]19,21,23,37].…”

“…Although these data effectively characterize the subtype spectrum of lymphomas [18][19][20][21][22][23][24][26][27][28][29][30][31][32][33][34][35], most studies have excluded the majority of plasma cell neoplasms and leukemias (circulating phase). Therefore, these results may not be comparable with population-based incidence data for the entire spectrum of WHO classifications [10,42,43].…”

“…The incidence and subtype distribution of lymphoid neoplasms shows marked variation worldwide, reflecting etiological heterogeneity with participation of both genetic and environmental factors in the lymphomagenesis [2,[4][5][6][7][8][9][10][11][12][13][14][15][16][17]. To describe the epidemiologic features of the entire spectrum of lymphoid neoplasms according to the WHO classifications, we examined the comprehensive cases of lymphoid neoplasms, including plasma cell neoplasms and lymphoid leukemias, diagnosed at a single hospital over two decades.…”

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

“…1 The clinical course of diff use large B-cell lymphoma has greatly changed over the past 10 years, since the introduction of the chimeric monoclonal anti-CD20 antibody rituximab for the treat ment of patients with lymphoma. A pivotal trial done in 1998 by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) showed that combining rituximab with standard cyclophospha mide, doxorubicin, vincristine, and predni sone (CHOP) chemo therapy signifi cantly improved response, event-free survival, and overall survival compared with CHOP alone in patients older than 60 years.…”

Salivary Gland Lymphoproliferative Disorders: A Canadian Tertiary Center Experience

“…Reactive lesions can mimic malignancy, a distinction which may be difficult. Fortunately, primary lymphomas of the SG are rare tumors, representing 1.7-3 % of all SG neoplasms [2,3], although the incidence may be on the rise [3][4][5].…”